Caitong International Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Caitong International Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1	Buy	+1	New	+$1	﹤0.01%	2460

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caitong International Asset Management's ATNM Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Actinium Pharmaceuticals (ATNM) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #2460 among its holdings.

54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Caitong International Asset Management held 1 share of Actinium Pharmaceuticals worth $1 as of Q1 2026.
Actinium Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
Actinium Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2460 holding.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.